Anavex Life Sciences (AVXL) Share-based Compensation (2010 - 2025)

Anavex Life Sciences (AVXL) has 16 years of Share-based Compensation data on file, last reported at $1.1 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation fell 46.13% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2025 stood at $13.9 million (up 51.18% YoY), and the FY2025 full-year result was $11.5 million, up 22.34% from the prior year.
• Share-based Compensation slipped to $1.1 million in Q4 2025, from $7.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $10.0 million in Q2 2025 to a low of $1.1 million in Q4 2025.
• A 5-year average of $3.8 million and a median of $3.3 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 377.08% in 2021 and plunged 56.87% in 2023, its largest moves.
• Tracing AVXL's Share-based Compensation over 5 years: stood at $3.9 million in 2021, then surged by 35.59% to $5.3 million in 2022, then plunged by 56.87% to $2.3 million in 2023, then retreated by 10.1% to $2.1 million in 2024, then slumped by 46.13% to $1.1 million in 2025.
• Business Quant data shows AVXL's Share-based Compensation at $1.1 million in Q4 2025, $7.2 million in Q3 2025, and $10.0 million in Q2 2025.